Abstract
Objectives To investigate clinical survey feasibility of pepsinogen ( PG) and CA724 as markers in the differential diagnosis of gastric cancer. Methods Enrolled patients were divided into three groups: gastric cancer 195 cases, chronic atrophic gastritis ( CAG) group 175 cases, normal control group 210 cases, according to the fibre gastroscopy and pathological cytology diagnosis.Pepsinogen Ⅰ( PG Ⅰ) and pepsinogen Ⅱ (PG Ⅱ) level were detected by immunoassay, then calculate the PGR( PG Ⅰ/PG Ⅱ) .Using electrochemi-luminescence immunoassay to qualitatively CA724 level. Results The gastric cancer group PGⅠ and PGR levels were significantly decreased than normal control group, with significant differences between the two groups (P=0.000); the content change of PG Ⅱ is little, no significant differences between the two groups (P=0.490) ; The CAG group PG Ⅰ and PGR levels were significantly lower than the normal control group, with significant differences between the two groups (P=0.003); the content change of PG Ⅱ is little, no significant differences between the two groups (P=0.407). PGR and PGⅠ had no statistical significance in gastric cancer group and CAG group (P=0.400) .CA724 levels in gastric cancer group was significantly higher than that of CAG group and the normal control group, the difference was statistically significant(P=0.003 ); but it had no significant differences in normal control group and CAG group (P=0.388). The PG sensitivity was 71.79%, specificity was 66.23% for diagnosis of gastric cancer, and the CA724 sensitivity was 41.28%, specificity was 92.2%.When combined PG and CA724 detection, the sensitivity was 82.67% and specificity was 73.59%.If both of the two detection were negative 82.78% exclude gastric cancer diagnosis. Conclusions If combined detection of the serum PG and CA724 are both negative, 82.78% gastric cancer can be discharged.It is feasible, as markers for gastric cancer differential diagnosis. Key words: Pepsinogen; Sugar antigen CA724; Gastric cancer; Chronic atrophic gastritis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
